Cargando…

Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases

OBJECTIVE: To evaluate the postoperative outcomes, safety and feasibility of percutaneous transforaminal endoscopic surgery (PTES) for the treatment of lumbar degenerative disease (LDD) in the patients with underlying diseases. METHODS: From June 2017 to April 2019, PTES was performed to treat 226 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tianyao, Ma, Tianle, Gu, Yutong, Zhang, Liang, Che, Wu, Wang, Yichao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072145/
https://www.ncbi.nlm.nih.gov/pubmed/37025953
http://dx.doi.org/10.2147/JPR.S396993
_version_ 1785019321970327552
author Zhou, Tianyao
Ma, Tianle
Gu, Yutong
Zhang, Liang
Che, Wu
Wang, Yichao
author_facet Zhou, Tianyao
Ma, Tianle
Gu, Yutong
Zhang, Liang
Che, Wu
Wang, Yichao
author_sort Zhou, Tianyao
collection PubMed
description OBJECTIVE: To evaluate the postoperative outcomes, safety and feasibility of percutaneous transforaminal endoscopic surgery (PTES) for the treatment of lumbar degenerative disease (LDD) in the patients with underlying diseases. METHODS: From June 2017 to April 2019, PTES was performed to treat 226 patients of single-level LDD. According to clinical background, the patients were divided into two groups. A total of 102 patients with underlying diseases were included in group A. The other 124 LDD patients without underlying diseases were included in group B. The occurrence of postoperative complications was recorded. Leg pain was assessed before, immediately, 1 month, 2 months, 3 months, 6 months, 1 year, and 2 years after PTES using VAS, and ODI before PTES and 2 years after PTES were recorded. The therapeutic quality (Excellent, Good, Moderate or Poor) was defined according to MacNab grade at 2-year follow-up. RESULTS: No aggravation of underlying diseases or serious complications was observed in all patients within 6 months after the operation. Altogether, 196 patients were followed up for more than 2 years, 89 patients in group A and 107 patients in group B. The VAS score of leg pain and ODI dropped significantly after surgery (P<0.001) in both groups. One case of group B received PTES again due to recurrence 52 months after surgery. According to MacNab, the excellent and good rate was 97.75% (87/89) in group A and 96.26% (103/107) in group B. In operative duration, frequency of intraoperative fluoroscopy, blood loss, incision length, hospital stay, VAS, ODI, and the excellent and good rate, there was no statistical difference between the two groups. CONCLUSION: PTES is safe, effective and feasible for the treatment of LDD with underlying diseases, which is comparable to PTES for LDD without underlying diseases. The entrance point of PTES (Gu’s Point) is located at the corner of the flat back turning to the lateral side. PTES is not only a minimally invasive surgical technique but also includes a postoperative care system for preventing LDD recurrence.
format Online
Article
Text
id pubmed-10072145
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100721452023-04-05 Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases Zhou, Tianyao Ma, Tianle Gu, Yutong Zhang, Liang Che, Wu Wang, Yichao J Pain Res Original Research OBJECTIVE: To evaluate the postoperative outcomes, safety and feasibility of percutaneous transforaminal endoscopic surgery (PTES) for the treatment of lumbar degenerative disease (LDD) in the patients with underlying diseases. METHODS: From June 2017 to April 2019, PTES was performed to treat 226 patients of single-level LDD. According to clinical background, the patients were divided into two groups. A total of 102 patients with underlying diseases were included in group A. The other 124 LDD patients without underlying diseases were included in group B. The occurrence of postoperative complications was recorded. Leg pain was assessed before, immediately, 1 month, 2 months, 3 months, 6 months, 1 year, and 2 years after PTES using VAS, and ODI before PTES and 2 years after PTES were recorded. The therapeutic quality (Excellent, Good, Moderate or Poor) was defined according to MacNab grade at 2-year follow-up. RESULTS: No aggravation of underlying diseases or serious complications was observed in all patients within 6 months after the operation. Altogether, 196 patients were followed up for more than 2 years, 89 patients in group A and 107 patients in group B. The VAS score of leg pain and ODI dropped significantly after surgery (P<0.001) in both groups. One case of group B received PTES again due to recurrence 52 months after surgery. According to MacNab, the excellent and good rate was 97.75% (87/89) in group A and 96.26% (103/107) in group B. In operative duration, frequency of intraoperative fluoroscopy, blood loss, incision length, hospital stay, VAS, ODI, and the excellent and good rate, there was no statistical difference between the two groups. CONCLUSION: PTES is safe, effective and feasible for the treatment of LDD with underlying diseases, which is comparable to PTES for LDD without underlying diseases. The entrance point of PTES (Gu’s Point) is located at the corner of the flat back turning to the lateral side. PTES is not only a minimally invasive surgical technique but also includes a postoperative care system for preventing LDD recurrence. Dove 2023-03-31 /pmc/articles/PMC10072145/ /pubmed/37025953 http://dx.doi.org/10.2147/JPR.S396993 Text en © 2023 Zhou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Tianyao
Ma, Tianle
Gu, Yutong
Zhang, Liang
Che, Wu
Wang, Yichao
Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title_full Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title_fullStr Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title_full_unstemmed Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title_short Percutaneous Transforaminal Endoscopic Surgery (PTES) for Treatment of Lumbar Degenerative Disease in Patients with Underlying Diseases: A Retrospective Cohort Study of 196 Cases
title_sort percutaneous transforaminal endoscopic surgery (ptes) for treatment of lumbar degenerative disease in patients with underlying diseases: a retrospective cohort study of 196 cases
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072145/
https://www.ncbi.nlm.nih.gov/pubmed/37025953
http://dx.doi.org/10.2147/JPR.S396993
work_keys_str_mv AT zhoutianyao percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases
AT matianle percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases
AT guyutong percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases
AT zhangliang percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases
AT chewu percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases
AT wangyichao percutaneoustransforaminalendoscopicsurgeryptesfortreatmentoflumbardegenerativediseaseinpatientswithunderlyingdiseasesaretrospectivecohortstudyof196cases